58662-50-3

Upstream product

• 20194-18-7 sodium phenyl-methanolate 
• 100-39-0 benzyl bromide 
• 621-59-0 isovanillin 
• 100-44-7 benzyl chloride 
• 712-97-0 6-nitro-1,3-benzodioxole-5-carbaldehyde 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 82583-98-0 5-Benzyloxy-4-hydroxy-2-nitro-benzaldehyde 
• 77-78-1 dimethyl sulfate 
• 58749-47-6 3-hydroxy-4-methoxy-6-nitrobenzaldehyde 

Downstream Products

• 58749-47-6 3-hydroxy-4-methoxy-6-nitrobenzaldehyde 
• 82584-00-7 3-benzyloxy-6-iodo-4-methoxybenzaldehyde 
• 107915-22-0 5-benzyloxy-4-methoxy-2-nitro-benzoyl chloride 
• 152715-42-9 1-(2'-amino-5'-hydroxy-4'-methoxyphenyl)-5,6,7-trimethoxy-3,4-dihydroisoquinoline 
• 152715-41-8 1-(3'-benzyloxy-4'-methoxy-6'-nitrophenyl)-5,6,7-trimethoxy-3,4-dihydroisoquinoline 
• 152715-40-7 5-benzyloxy-4-methoxy-2-nitro-N-<2'-(2'',3'',4''-trimethoxyphenyl)ethyl>benzamide 
• 1426813-87-7 6-benzyloxy-7-methoxy-2-methyl-N-(n-pentyl)quinoline-3-carboxamide 
• 199327-61-2 7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one 
• 1494468-50-6 C₁₆H₁₄N₂O₂ 
• 286371-64-0 6-(benzyloxy)-7-methoxyquinazolin-4(3H)-one 
• 179688-52-9 6-hydroxy-7-methoxyquinazolin-4(3H)-one 

Relevant academic research and scientific papers

Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations

Targeted concurrent inhibition of intestinal drug efflux transporter P-glycoprotein (P-gp) and drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is a promising approach to improve oral bioavailability of their common substrates such as docetaxel, while avoiding side effects arising from their pan inhibitions. Herein, we report the discovery and characterization of potent small molecule inhibitors of P-gp and CYP3A4 with encequidar (minimally absorbed P-gp inhibitor) as a starting point for optimization. To aid in the design of these dual inhibitors, we solved the high-resolution cryo-EM structure of encequidar bound to human P-gp. The structure guided us to prudently decorate the encequidar scaffold with CYP3A4 pharmacophores, leading to the identification of several analogues with dual potency against P-gp and CYP3A4. In vivo, dual P-gp and CYP3A4 inhibitor 3a improved the oral absorption of docetaxel by 3-fold as compared to vehicle, while 3a itself remained poorly absorbed.

Pyrrolo[2,1-c][1,4] benzodiazepine-3,11-diones protect SHSY-5Y cells from Cd-induced apoptosis involving suppression of endoplasmic reticulum stress

Cadmium (Cd) is a potent toxic heavy metal, some studies showed that Cd-induced apoptosis is through ER stress pathway. Compounds of pyrrolo[2,1–c][1,4]benzodiazepine (PBD)-3,11-diones were discovered as potent neuroprotective agents against Cd-induced toxicity in SH-SY5Y cells for the first time. In this study, twenty-six PBD-3,11-dione derivatives were synthesized and evaluated for their neuroprotective activity against Cd-induced toxicity by CCK-8 assay. Their preliminary SARs studies indicated that various substituents were tolerated on the benzene ring, and alkyl heterocycles groups at the N10-position of the PBD-3,11-dione scaffold were important for the activities. Among them, compound 13c exhibited the best activity (cell viability = 68.6%, 25 μM). Furthermore, we found that the compound 13c could inhibit cadmium-induced cell apoptosis with the downregulation of the ER stress markers GRP78, CHOP, cleaved-caspase12 and cleaved-caspase3 through western blotting. The results of in silico evaluation of ADME/T properties showed that 13c exhibited medium BBB penetration level and promising toxicity profiles. These results proved the potential of 13c as a promising lead compound against Cd-induced neurotoxicity.

3-heterocycle substituted quinoline derivatives as well as preparation method and applications thereof

The invention relates to new quinoline derivatives shown in a general formula I and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and wherein substituent R1, R2, R3 and n contain meanings shown in the specification. The invention also relates to an enhanced effect of the compounds shown in formula I for inhibiting DNA duplication of HBV, and also relates to applications of the compounds and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof to preparation of medicaments for treating diseases due to infection of HBV, and especially relates to applications of medicaments for treating and/or preventing viral hepatitis B.

Synthesis and Anti-Hepatitis B Virus Evaluation of 7-Methoxy-3-heterocyclic quinolin-6-ols

A series of novel 7-methoxy-3-heterocyclic quinolin-6-ol derivatives were synthesized and evaluated for their anti-hepatitis B virus (HBV) activities and cytotoxicities in the HepG2.2.15 cell line. Five compounds, 14a, 15c, 15e, 16b, and 16f, displayed ex

Facile and efficient oxidation of quinazolines into quinazolin-4(3 H)-ones by peracetic acid

A new approach to synthesize quinazoline-4(3H)-ones was achieved by oxidation of quinazolines using peracetic acid, which possesses some advantages of economic reagents, simplified operation, high efficiency, and environmental friendliness. Application of this method allowed us to synthesize a series of quinazolin-4(3H)-ones with different substituents at 6 and 7 positions in good to excellent yields, including the key intermediates of tyrosine kinase inhibitors such as PD153035, Erlotinib, and Gefitinib. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]

Quinoline-3-carboxamide derivatives as potential cholesteryl ester transfer protein inhibitors

A series of novel quinoline-3-carboxamide derivatives 10-17 and 23-27 were designed and synthesized as cholesteryl ester transfer protein (CETP) inhibitors. All of them exhibited activity against CETP. Particularly, compounds 24 and 26 displayed the best activity against CETP with the same inhibitory rate of 80.1%.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols

A series of novel 6H-[1]benzothiopyrano[4,3-b]quinoline derivatives were prepared and evaluated for their anti-hepatitis B virus (HBV) activity and cytotoxicity in human hepatoblastoma-derived liver Hep-G2 cells. Compounds 10g, 10h, 10j, 10l and 10o were found to be potent anti-HBV compounds with IC50 values less than 50 μM. The most promising compound was 10l, with an IC50 value of 14.7 μM and a SI value of 12.4. This is the first report of the anti-HBV effects of 6H-[1]benzothiopyrano[4,3-b] quinolin-9-ols. Crown Copyright

Solid phase synthesis of a redox delivery system with the aim of targeting peptides into the brain

A solid phase approach for the preparation of peptides attached to a redox chemical delivery system derived from stable annulated NADH models is reported. The synthesis starts with the grafting on a Merrifield resin of quinoline 4b, precursor of the redox

Studies Directed Towards Total Syntheses of the Tropoloisoquinoline Alkaloids Grandirubrine and Imerubrine. Part 2. Thermolysis of 8,9-Dihydro-2-hydroxy-3,10,11,12-tetramethoxyisoquinobenzotriazin-7-ium Chloride: Competitive Modes of Cyclisa

Thermolysis of the title compound 8 produced not only the expected azafluoranthene 7 but also the regioisomeric compound 23 and its dihydro counterpart 22.A mechanism for the formation of compounds 7, 22 and 23 from precursor 8 has been advanced.Reaction